natgillin/translations-raw huggingface dataset:
De fleste forsøgspersoner (N=1370) modtog behandling i en periode på mindst 12 uger, og 409 blev eksponeret i mindst 52 uger (1 år).
Most subjects (N=1370) had a treatment period of at least 12 weeks and 409 had at least 52 weeks (1 year) of exposure.
De fleste hallucinationer er syns- hallucinationer
Most hallucinations are visual.
De fleste hudreaktioner var begrænset til applikationsstedet og resulterede kun i afbrydelse hos 2,4% af patienterne i ivastigmin 9,5 mg/24 timer depotplastre-behandlingsgruppen.
Most skin reactions were limited to the application site and resulted in discontinuation in only 2.4% of the patients in the rivastigmine 9.5 mg/24 h transdermal patch group.
De fleste hæmatologiske bivirkninger blev håndteret ved hjælp af rutinemæssig komplet blodtælling kombineret med udsættelse af næste cyklus af azacitidin, profylaktiske antibiotika og/eller understøttende behandling med vækstfaktorer (f.eks.
Most haematological adverse reactions were managed by routine monitoring of complete blood counts and delaying azacitidine administration in the next cycle, prophylactic antibiotics and/or growth factor support (e.g.
De fleste hæmatologiske bivirkninger blev rapporteret som værende almindelige eller meget almindelige for begge indikationer (Tabel 4 og 5); hyppighed af grad 3-4 laboratoriefund er angivet efter hver tabel.
Most haematological adverse reactions were reported commonly or very commonly in both indications (Tables 4 and 5); the frequency of grade 3-4 laboratory findings is presented after each table.
De fleste imatinib-intolerante patienter med CML i kronisk fase kunne tåle behandling med SPRYCEL.
The majority of imatinib-intolerant patients with chronic phase CML were able to tolerate treatment with SPRYCEL.
De fleste invasive SPM’er var maligniteter med solide tumorer.
Most of the invasive SPMs were solid tumour malignancies.
De fleste IRR'er var milde eller moderate i intensitet, og <1 % resulterede i seponering af studiebehandlingen.
The majority of IRRs were mild or moderate in intensity and <1% resulted in discontinuation of study treatment.
De fleste ISR’er varede i en eller to dage.
Most ISRs lasted for one to two days.
De fleste lægemiddelinteraktionsstudier med saquinavir er udført med ikke-boostet Invirase eller ikke- boostet saquinavir bløde kapsler.
Most drug interaction studies with saquinavir have been completed with unboosted Invirase or unboosted saquinavir soft capsules.
De fleste mennesker kommer sig fuldstændigt, men sygdommen er almindeligvist alvorlig nok til at holde folk hjemme fra arbejde i ca. en måned.
Most people recover completely but the illness is usually severe enough to keep people off work for about a month.
De fleste mennesker vil ikke have været i kontakt med den før og har derfor ikke udviklet en beskyttelse ("immunitet") mod den.
Most people will not have come into contact with it and therefore will not have built up protection (‘immunity’) against it.
De fleste mindre alvorlige reaktioner på insulin forsvinder som regel i løbet af et par dage til et par uger.
Most minor reactions to insulins usually resolve in a few days to a few weeks.
De fleste mindre reaktioner på insulin forsvinder som regel i løbet af et par dage til et par uger.
Most minor reactions to insulins usually resolve in a few days to a few weeks.
De fleste overfølsomhedsreaktioner over for asparaginase observeres i løbet af efterfølgende behandlingsfaser (behandling med gentagen induktion, forsinket intensivering).
Most hypersensitivity reactions to asparaginase are observed during subsequent treatment phases (re- induction treatment, delayed intensification).
De fleste patienter (87 %) i ITT- populationen havde BRAF V600E-mutationen, og 12 % af patienterne havde BRAF V600K- mutationen.
Most patients (87%) in the ITT population had BRAF V600E mutation and 12% of patients had BRAF V600K.
De fleste patienter (> 89 %) i såvel gruppe A som gruppe B opnåede komplet antidoteffekt målt ved dTT eller ECT i de første 4 timer efter administration af 5 g idarucizumab.
Most patients (>89%), in both Groups A and B, achieved complete reversal of the anticoagulant effect of dabigatran as measured by dTT or ECT in the first 4 hours after administration of 5 g idarucizumab.
De fleste patienter (meget almindeligt, forekommer hos flere end 1 ud af 10 personer) får et lavere niveau af jern i blodet.
Most people (very common may affect more than 1 in 10 people) get lower levels of iron in their blood.
De fleste patienter fik MabThera i kombination med med kemoterapi eller som en del af en hæmatopoietisk stamcelletransplantation.
The majority of patients had received MabThera in combination with chemotherapy or as part of a haematopoetic stem cell transplant.
De fleste patienter havde AJCC-stadie IV sygdom (93%); 58% havde sygdomsstadie M1c ved inklusion i studiet.
The majority of the patients had AJCC Stage IV disease (93%); 58% had M1c disease at study entry.
De fleste patienter havde ECOG-performance-score 0 (64%) eller 1 (34%).
Most patients had ECOG performance score of 0 (64%) or 1 (34%).
De fleste patienter havde forhøjede niveauer, som var asymptomatiske og forsvandt spontant.
Most patients had elevations that were asymptomatic and resolved spontaneously.
De fleste patienter havde tidligere fået andre lægemidler, men var nødt til at ændre behandling.
Most patients had previously received other medicines but needed to change treatment.
De fleste patienter i de kliniske studier (>84 %) var kaukasiere.
Most patients in the clinical trials (> 84%) were Caucasian.
De fleste patienter i dette studie (71%, herunder 98% med tidligere mislykket PI-behandling) havde IL- 28B rs12979860 non-CC-genotyper.
Most patients (71%, including 98% of prior PI failures) had IL-28B rs12979860 non-CC genotypes.
De fleste patienter i disse studier fik immunmodulerende behandling.
The majority of patients in these studies were using immunomodulatory medicines.
De fleste patienter i disse tre forsøg havde effekt af tidligere p.n.-behandling med PDE5-inhibitorer.
Most patients in these three studies were responders to previous on- demand treatment with PDE5 inhibitors.
De fleste patienter i disse tre forsøg havde effekt af tidligere p.n.-behandling med PDE5-inhibitorer.
Most patients in these three studies were responders to previous on-demand treatment with PDE5 inhibitors.
De fleste patienter i kontrollerede kliniske forsøg fik antihistaminer og/eller antipyretika før mindst én LEMTRADA-infusion.
Most patients in controlled clinical trials received antihistamines and/or antipyretics before at least one LEMTRADA infusion.
De fleste patienter i studiet var kvinder (73 %), hvide (69 %) og kemoterapi- behandlingsnaive (59 %).
The majority of patients in the study were women (73 %), white (69 %), and naïve to previous chemotherapy (59 %).
De fleste patienter kom i bedring efter seponering af Leflunomid Winthrop.
Most patients improved after discontinuation of leflunomide.
De fleste patienter med Parkinsons sygdom på et fremskredent stadium når den passende dosis inden for 3 til 7 uger ved doser på 8 mg dagligt op til en maksimal dosis på 16 mg dagligt.
For most patients with advanced-stage Parkinson’s disease the right dose is reached within 3 to 7 weeks, at doses of 8 mg per day up to a maximum dose of 16 mg per day.
De fleste patienter med positiv test for antistoffer mod ustekinumab havde neutraliserende antistoffer.
The majority of patients who were positive for antibodies to ustekinumab had neutralizing antibodies.
De fleste patienter oplever kuldegysninger (89 %), feber (85 %) og træthed (53 %).
The majority of patients experience chills (89%), fever (85%) and fatigue (53%).
De fleste patienter på tværs af alle behandlingsgrupper var ikke kemoterapinaive (78,5 %).
Most patients were non-naive to chemotherapy (78.5%) across all treatment groups.
De fleste patienter serokonverterede inden for 3 måneder fra påbegyndelse af behandling; dog opstod serokonvertering hos patienter under 5 år med en mere alvorlig fænotype oftest inden for 1 måned (mean 26 dage mod 45 dage hos patienter, der var 5 år eller ældre).
Most patients seroconverted within months of initiation of treatment; although seroconversion in patients under 5 years old with a more severe phenotype occurred mostly within 1 month (mean 26 days versus 45 days in patients 5 years and older).
De fleste patienter skal have 6 til 9 inhalationsbehandlinger, fordelt på hele dagen.
Most people will have 6 to 9 inhalation sessions spread throughout the day.
De fleste patienter var ikke tidligere behandlet for hepatitis C, om end nogle af dem var smittet med virus af genotype 1, der var resistent mod sædvanlige lægemidler (bestående af telaprevir eller boceprevir – de såkaldte NS3/4A-hæmmere – kombineret med peginterferon alfa og ribavirin).
Most patients had not previously been treated for hepatitis C, though some had genotype 1 infection that was resistant to standard medicines (consisting of either telaprevir or boceprevir – the so-called NS3/4A inhibitors - in combination with peginterferon alfa and ribavirin).
De fleste patienter var ikke-asiatiske (81,6 %), medianalderen var 60,0 år, ECOG- funktionsstatus ved baseline var 0 (28,6 %) eller 1 (71,3 %); en enkelt patient havde en ECOG- funktionsstatus på 2 ved baseline.
The majority of patients were non-Asian (81.6 %), the median age was 60.0 years, the baseline ECOG performance status was 0 (28.6 %) or 1 (71.3 %); one patient had a baseline ECOG performance status of 2.
De fleste patienter var ved baseline klassificeret i WHO-funktionsklasse II (107/277, 39%) eller III (160/277, 58%) med en gennemsnitlig 6 minutters gangdistance på hhv.
Most patients were WHO Functional Class II (107/277, 39 %) or III (160/277, 58 %) with a mean baseline 6 minute walking distance of
De fleste patienter vil få en reversibel rødfarvning af hud og slimhinder, der kan vare i op til 15 dage efter administration af Cyanokit.
Most patients will experience a reversible red colouration of the skin and mucous membranes that may last up to 15 days after administration of Cyanokit.
De fleste patienter vil ikke have behov for at afslutte TRISENOX-terapi under behandling af RA-APL syndromet.
The majority of patients do not require termination of TRISENOX therapy during treatment of the APL differentiation syndrome.
De fleste patienter, der anvendte Zyclara til behandling af AK fik lokale hudreaktioner (ofte erythem, skorpedannelse og afskalning/tørhed) på applikationsstedet.
Most patients using Zyclara for the treatment of AK experience local skin reactions (most frequently erythema, scab, and exfoliation/application site dryness) at the application site.
De fleste patienter, der behandles med thalidomid, oplever bivirkninger.
Most patients taking thalidomide experience side effects.
De fleste patienter, der responderede på NeuroBloc i den fjerde uge, vendte tilbage til deres oprindelige tilstand 12-16 uger efter injektionen.
Most patients who had a response to NeuroBloc by the fourth week had returned to their original condition 12 to 16 weeks after the injection.
De fleste patienter, som disse hændelser blev rapporteret hos, havde allerede eksisterende kardiovaskulære risikofaktorer.
Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors.
De fleste patienter, som fik 2 mg Rapamune 4 timer efter ciclosporin, havde sirolimus-dalkoncen- trationer i fuldblod inden for intervallet 4-12 ng/ml (udtrykt som kromatografisk analyseværdi).
Most patients who received 2 mg of Rapamune 4 hours after ciclosporin had whole blood trough concentrations of sirolimus within the 4 to 12 ng/mL target range (expressed as chromatographic assay values).
De fleste patienter, som fik 2 mg Rapamune 4 timer efter ciclosporin, havde sirolimus-dalkoncentra- tioner i fuldblod inden for intervallet 4-12 ng/ml (udtrykt som kromatografisk analyseværdi).
Most patients who received 2 mg of Rapamune 4 hours after ciclosporin had whole blood trough concentrations of sirolimus within the 4 to 12 ng/mL target range (expressed as chromatographic assay values).
De fleste patienter, som oplevede kongestiv hjerteinsufficiens eller asymptomatisk kardiel dysfunktion i de pivotale studier, opnåede en bedring med en standardbehandling af kongestiv hjerteinsufficiens bestående af en ACE-hæmmer eller angiotensin II receptor-antagonist og en betablokker.
Most patients who developed CHF or asymptomatic cardiac dysfunction in pivotal trials improved with standard CHF treatment consisting of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and a beta-blocker.
De fleste patienter, som oplever virologisk svigt under en abacavir behandling i et pivotalt klinisk studie med Combivir (fastdosiskombination med lamivudin og zidovudin), viste enten ingen NRTI-relaterede ændringer i forhold til baseline (15 %) eller kun M184V- eller M1841- mutationer (78 %).
Most patients experiencing virological failure with a regimen containing abacavir in a pivotal clinical trial with Combivir (fixed dose combination of lamivudine and zidovudine) showed either no NRTI-related changes from baseline (15 %) or only M184V or M184I selection (78 %).
De fleste rapporter om overdosering var ikke forbundet med uønskede hændelser og sværhedsgraden var mild til moderat.
Most reports of overdose were not associated to adverse events, and severity was mild to moderate.
De fleste rapporterede bivirkninger er forbigående og af mild intensitet.
Most of the side effects reported were transient and of mild intensity.
De fleste reaktioner var milde til moderate i sværhedsgrad og ikke langvarige.
The majority of these reactions were of mild to moderate severity and were not long lasting.
De fleste respondenter nåede et HR tidligt med Tasigna-behandling (median 1,0 måned), og de har været vedvarende (medianvarighed på den bekræftede HR var 24,2 måneder).
Most responders achieved a HR early with Tasigna treatment (median 1.0 months) and these have been durable (median duration of confirmed HR was 24.2 months).
De fleste respondenter opnåede MCyR hurtigt inden for 3 måneder (median 2,8 måneder) efter start af Tasigna-behandlingen, og det blev opretholdt.
Most responders achieved their MCyR rapidly within 3 months (median 2.8 months) of starting Tasigna treatment and these were sustained.
De fleste SPRYCEL-behandlede patienter oplevede bivirkninger på et tidspunkt.
The majority of SPRYCEL-treated patients experienced adverse reactions at some time.
De fleste tilfæ lde af unormale aminotransferaser var forbigående; et lille antal patienter oplevede imidlertid mere langvarige stigninger.
Most aminotransferase abnormalities were transient; however, a small number of patients experienced more prolonged elevations.
De fleste tilfælde af aspergillose blev vurderet som værende refraktære for tidligere terapi både i posaconazolgruppen (88 %) og i den eksterne kontrolgruppe (79 %).
Most of the cases of aspergillosis were considered to be refractory to prior therapy in both the posaconazole group (88 %) and in the external control group (79 %).
De fleste tilfælde af dyspnø var milde eller moderate og varede i gennemsnit 2 timer hos patienter, som fik cangrelor (se pkt.
Most dyspnoea events were mild or moderate in severity and the median duration of dyspnoea was two hours in patients receiving cangrelor, (see section 4.8).
De fleste tilfælde af perifere ødemer, der blev observeret i kliniske studier med ambrisentan, var lette til moderate, men hos patienterne ≥ 65 år kan ødemer forekomme med større hyppighed, og være mere alvorlige.
Most cases of peripheral oedema in clinical studies with ambrisentan were mild to moderate in severity, although it may occur with greater frequency and severity in patients ≥65 years.
De fleste tilfælde af unormal leverfunktion/leversygdom fra post-marketing erfaring forekom hos japanske patienter.
Most cases of hepatic function abnormal / liver disorder from post-marketing experience occurredin Japanese patients.
De fleste tilfælde blev klassificeret som lette til moderate.
Most cases were classed as mild or moderate.
De fleste tilfælde indtraf i løbet af den første behandlingsmåned og normaliseredes efter seponering af ZYTIGA.
Most cases developed within the first month of treatment and recovered after ZYTIGA withdrawal.
De fleste typer brystkræft vokser ved påvirkning af hormonet østrogen.
Most types of breast cancer grow in response to the hormone oestrogen.
De fleste tyrosinkinasehæmmere
Most tyrosine kinase inhibitors
De fleste tyrosinkinasehæmmere sådan som dasatinib og nilotinib, vincristin, vinblastin
Most tyrosine kinase inhibitors such as dasatinib and nilotinib, Vincristine, Vinblastine
De fleste var af grad 1/2, og intervention var ikke nødvendig.
Most were Grade 1/2 in severity and manageable without intervention.
De fleste var okulære og af let grad.
Most were ocular and of mild severity.
De fleste var okulære, lette til moderate, og ingen var alvorlige:
Most were ocular, mild and none was serious:
De fleste, der får disse gener, finder frem til, hvordan de kan kontrollere dem ved at ændre kosten.
Most users who experience these effects find that they can manage and control them by adjusting their diet.
De for nylig har haft hypoglykæmi (f.eks. dagen før), eller hvis tilstanden udvikles langsomt,
you have recently suffered hypoglycaemia (e.g. the day before) or if it develops slowly,
De for nylig har haft hypoglykæmi (f.eks. dagen før), eller hvis tilstanden udvikles langsomt,
you have recently suffered hypoglycaemia (for example the day before) or if it develops slowly,
De for nyligt har fået, eller forventer snart at få, en levertransplantation
you have recently had, or soon expect to have, a liver transplant
De fordele, der blev observeret for clopidogrel, var uafhængige af anden akut og langvarig behandling af kardiovaskulære sygdomme (med fx heparin/LMWH, GPIIb/IIIa-hæmmere, lipidsænkende lægemidler, beta- blokkere og ACE-hæmmere).
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors).
De forelagte oplysninger var imidlertid ikke tilstrækkelige til at underbygge brugen af Invanz til behandling af urinvejsinfektioner og infektioner i hud og underliggende væv, bortset fra fodsår hos sukkersygepatienter.
However, the data presented were not sufficient to support the use of Invanz in the treatment of urinary tract infections and skin and soft tissue infections, except diabetic foot ulcers.
De forelagte oplysninger var utilstrækkelige som dokumentation for anvendelsen af Altargo til be- handling af inficeret dermatitis.
The data presented were insufficient to support the use of Altargo in the treatment of infected dermatitis.
De foreliggende data antyder ikke et behov for en dosisregulering med Eylea hos disse patienter (se pkt.
Available data do not suggest a need for a dose adjustment with Eylea in these patients (see section 5.2)
De foreliggende data er beskrevet i pkt.
Current available data are described in sections 4.8,
De foreliggende data er beskrevet i pkt.
Currently available data are described in section 4.8,
De foreliggende data er beskrevet i pkt.
Currently available data are described in section 4.8, 5.1 and
De foreliggende data er beskrevet i pkt.
Currently available data are described in section 5.2.
De foreliggende oplysninger er baseret på data fra kliniske forsøg, hvor 115 patienter (> 1 og  21 år) enten med ALL eller akut myeloid leukæmi (AML) fik mindst én dosis clofarabin i den anbefalede dosis på 52 mg/m2 dagligt x 5.
The information provided is based on data generated from clinical trials in which 115 patients (> 1 and ≤ 21 years old) with either ALL or acute myeloid leukaemia (AML) received at least one dose of clofarabine at the recommended dose of 52 mg/m2 daily x 5.
De foreløbige data fra en supplerende undersøgelser stemmer overens med resultatet af hovedundersøgelsen, hvor 46 % af patienterne responderede på behandling efter 12 uger.
Preliminary data from a supportive study are consistent with the result of the main study, with 46% of patients responding to treatment after 12 weeks.
De foreløbige rapporter indsendes hvert 2. år, indtil den sidste patient er blevet fulgt i 5 år.
The interim reports will be submitted every two years until the final patient is followed for 5 years.
De foreløbige resultater fra 30 patienter viser, at talimogen laherparepvec-DNA blev påvist ved flygtige og lave koncentrationer i blod hos 90% af patienterne og i urin hos 20% af patienterne i studiet.
Interim results from 30 patients show that talimogene laherparepvec DNA was detected at transient and low concentrations in blood in 90% of patients and in urine in 20% of patients in the study.
De foreløbige resultater viste en øget risiko for død og alvorlige hændelser hos patienter, der fik riociguat, sammenlignet med patienter, der fik placebo.
Interim results showed an increased risk of mortality and serious adverse events in subjects receiving riociguat compared to those receiving placebo.
De foretagne undersøgelser viser, at Bosulif er effektivt til at nedsætte andelen af hvide blodlegemer med philadelphiakromosomet.
Studies have been carried out to show that Bosulif is effective at reducing the proportion of white blood cells with the Philadelphia chromosome.
De forholdsregler, der træffes for at garantere sikkerheden ved brug af Omnitrope, hænger sammen med grundene til, at lægemidlet anvendes.
The measures taken to ensure the safe use of Omnitrope are linked to the reasons why the medicine is used.
De forskellige dyrearter, som veterinærlægemidlet er beregnet til, indtager forskellige typer foder, og deres stofskifte omsætter lægemidlet forskelligt.
The different target species consume different types of food and exhibit differing metabolism.
De forsøgspersoner, der tidligere havde fået 2 eller flere doser 23-valent pneumokok polysaccharidvaccine, havde et tilsvarende immunrespons som de personer, der tidligere havde fået en enkelt dosis
Subjects who received two or more previous doses of 23-valent pneumococcal polysaccharide vaccine showed a similar immune response compared with subjects who received a single previous dose.
De forsøgspersoner, hvis prøver har en konsekvent stigning i urin-GAG værdierne sammen med høje antistofniveauer, vil få deres antistofprøver vurderet for tegn på neutraliserende aktiviteter.
Samples from those subjects who have a consistent increase in urinary GAG values together with high antibody levels will have their antibody samples assessed for evidence of neutralizing
De foruddefinerede kategorier var reduktioner i procent, der gik fra en reduktion på 90-100 % til ingen reduktion af prednison- dosis fra afslutningen af optimeringsfasen.
Predefined categories included percent reductions ranging from 90-100% reduction, to no decrease in the prednisone dose from the end of the optimisation phase.
De forudsagte eksponeringer med 84 mg eliglustat en gang om dagen hos patienter, som er PM’er, forventes at ligne de eksponeringer, der blev observeret med 84 mg eliglustat to gange dagligt hos CYP2D6-intermediære metabolisatorer (IM’er).
The predicted exposures with 84 mg eliglustat once daily in patients who are PMs are expected to be similar to exposures observed with 84 mg eliglustat twice daily in CYP2D6 intermediate metabolisers (IMs).
De forventede bivirkninger vil relateres til den farmakodynamiske profil for en dopaminagonist herunder kvalme, opkastning, hyperkinesi, hallucinationer, agitation og hypotension.
The expected adverse events would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension.
De forventede depleteringer af B- og T-celler blev observeret hos drægtige mus, men de hæmatologiske virkninger blev ikke undersøgt på fostre.
The expected depletions of B- and T-cells were observed in the pregnant mice but haematological effects were not assessed in foetuses.